EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Republic Healthcare Ltd (8357) fair value: what the stock is really worth

As of Sep 22, 2026: fair value of Republic Healthcare Ltd HK$0.04, price HK$0.09, upside -54.9%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · HK · ISIN KYG7516A1022

RH Thin data Sep 24, 2026

Republic Healthcare Ltd

8357 · HK

Weakest SetupStrongly overvalued and low quality.

!Fair value HK$0.0383 · Strongly overvalued (−55%)
!Quality 38/100
!Weak Growth (revenue 5y −10.8 %/yr)
!Loss-making · -36.9% net margin (TTM)
!negative free cash flow
!Trails peers (1/9)
!Narrow moat 3/100
!Evidence only low, so the estimate is less certain
Watch Republic Healthcare Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$0.6500 HK$0.0520 Fair Value HK$0.0383 Mar 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range HK$0.0520 – HK$0.6500 · fair‑value band HK$0.0298 – HK$0.0383 · the HK$0.0850 price screens above the HK$0.0383 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Republic Healthcare in your weekly email

Every Wednesday you see whether Republic Healthcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Republic Healthcare Limited, an investment holding company, operates a network of general practice medical clinics under the Dr. Tan & Partners (DTAP) brand in Singapore and the People's Republic of China. It operates through Medical Services and Education Services segments.

Show more

Republic Healthcare Limited, an investment holding company, operates a network of general practice medical clinics under the Dr. Tan & Partners (DTAP) brand in Singapore and the People's Republic of China. It operates through Medical Services and Education Services segments. The company offers consultation, medical investigation, and treatment; men's, women's, and sexual health; health management; management advisory; and healthcare-related education and educational support services. It also provides its services under the S Aesthetics Clinic (SAC) and California Metropolitan University (CMU) brands. Republic Healthcare Limited was founded in 2010 and is headquartered in Singapore.

Stock analysis

Republic Healthcare Ltd (8357) currently trades at HK$0.0850, while our model-based Fair Value estimate is HK$0.0383, implying the stock looks roughly 121.9% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: HK$0.0298 (bear) to HK$0.0383 (bull), the price of HK$0.0850 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Republic Healthcare Ltd reported revenue of 7.8M SGD in FY2025 versus 14.0M SGD in FY2021, a compound −13.4%/yr. Reported net income was −3.0M SGD in FY2025.

Key figures

Market cap HK$79.9M (≈ $10.2M) · P/S ratio 9.81 · Net margin −37.8% · Return on equity −27.2% · Return on assets (EBIT) 1.5% · Operating margin −43.9% · Revenue (TTM) HK$8.1M · Revenue growth (YoY) −8.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 65% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −55%, 8357 screens richer than that median.

Fair Value models

Bear HK$0.0298 Fair Value HK$0.0383 Bull HK$0.0383
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) HK$0.0100 HK$0.0100 HK$0.0200 50
All 1 models by family
Asset-Based
NCAV (Graham) HK$0.0100 HK$0.0100 HK$0.0200 50

Open the full fair value analysis →

Notify me when 8357 reaches fair value

Put 8357 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 38/100

Of which business quality 41 · Market factors (momentum, volatility) 10

Profitability 6
Margins and returns on capital today
Quality Growth 0
Are margins and returns improving?
Cashflow 3
Earnings quality: real cash, not paper profit
Fin. Strength 97
Balance sheet, leverage, solvency risk
Investment 75
Disciplined investing over empire-building
Low Volatility 16
Calm price path (market factor)
Momentum 10
Price trend over the last 3–12 months (market factor)
52W Momentum 4
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−15.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.8%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
9.0% (2019) → −34.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

8357 screens 122% overvalued. Compare with HCA Healthcare, Inc →

Compare Republic Healthcare Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 261 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Bottom 25%
Fair Value upside −55% · Bottom 25%
Profitability
Return on assets −13% · Bottom 25%
Net margin (TTM) −37% · Bottom 25%
Operating margin (TTM) −44% · Bottom 25%
Growth and dividend
Revenue growth −8% · Bottom 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 1.07× · Cheaper than median
P/S (TTM) 1.25× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $438.12 $592.64 +35%
Fresenius SE FRE €45.57 €34.54 −24%
Dr. Sulaiman Al Habib Medical Services Group 4013 227.50 SAR 109.45 SAR −52%
IHH Healthcare Berhad, an investment holding company, Q0F 2.48 SGD 1.63 SGD −34%
Tenet Healthcare Corporation THC $262.06 $399.58 +52%
DaVita Inc DVA $183.72 $255.97 +39%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,836 ₹2,908 −67%
Fresenius Medical Care AG FME €39.30 €71.28 +81%
Aier Eye Hospital Group 300015 ¥8.07 ¥10.86 +35%
Encompass Health Corporation EHC $122.76 $96.51 −21%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Republic Healthcare Ltd · Fair Value
HK$0.0383 −122%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Republic Healthcare Ltd Fair Value". https://www.fairvalue-calculator.com/stock/8357

Frequently asked questions

Is Republic Healthcare Ltd (8357) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of HK$0.0383 versus a price of HK$0.0850, about −55% upside (overvalued).
What is the fair value of 8357?
Our model-based fair value for Republic Healthcare Ltd is HK$0.0383 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$0.0850.
What is the quality score of 8357?
Republic Healthcare Ltd has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Republic Healthcare Ltd (8357)?
Our model-based price target is the fair value of HK$0.0383 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario HK$0.0298, optimistic scenario HK$0.0383. It is a calculation from audited fundamentals, not an analyst target.
What is the Republic Healthcare Ltd stock forecast for 2026?
Our models put fair value at HK$0.0383, about −55% upside versus a price of HK$0.0850 (overvalued). Cautious scenario HK$0.0298, optimistic scenario HK$0.0383. The calculation is refreshed regularly with new filings.
What is the revenue of Republic Healthcare Ltd (8357)?
Republic Healthcare Ltd reported trailing-twelve-month revenue of about HK$8.1M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Republic Healthcare Ltd (8357)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Republic Healthcare Ltd it is HK$0.0383 per share (as of Sep 24, 2026), against a price of HK$0.0850. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Republic Healthcare Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 8357 trades above its calculated fair value: price HK$0.0850, fair value HK$0.0383, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 8357?
No. The price is what the market pays today (HK$0.0850); the fair value is what the company's own numbers justify (HK$0.0383). For Republic Healthcare Ltd the two are HK$0.0467 per share apart. That gap is exactly why we show both numbers side by side.
How much is Republic Healthcare Ltd worth?
The market values Republic Healthcare Ltd at about HK$79.9M (market capitalisation, as of Sep 24, 2026). Per share that is HK$0.0850; our models calculate a fair value of HK$0.0383 per share.
What do the bullish and bearish scenarios say about 8357?
Our models span a range for Republic Healthcare Ltd: cautious scenario HK$0.0298, base HK$0.0383, optimistic HK$0.0383 per share (as of Sep 24, 2026, price HK$0.0850). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Republic Healthcare Ltd (8357)?
Balance-sheet figures for Republic Healthcare Ltd (as of Sep 24, 2026): return on equity −27.2%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is 8357 from its 52-week high?
Republic Healthcare Ltd trades at HK$0.0850, about 65% below its 52-week high of HK$0.2400 and 16% above the low of HK$0.0730 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.0383 is for.
Which stocks are comparable to Republic Healthcare Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Republic Healthcare Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price HK$0.0850, calculated fair value HK$0.0383 (−55%), Quality Score 38/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 8357 calculated?
We run Republic Healthcare Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.0383, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Republic Healthcare Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Republic Healthcare Ltd (8357)?
The closing price on Sep 22, 2026 was HK$0.0850. Our model-based fair value is HK$0.0383, about −55% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Republic Healthcare Ltd right now?
The price sits above even our optimistic bull case (HK$0.0383). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Republic Healthcare Ltd

How large is the market capitalisation of Republic Healthcare Ltd (8357)?
The market capitalisation of Republic Healthcare Ltd is HK$79.9M (≈ $10.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Republic Healthcare Ltd (8357)?
The price-to-sales ratio of Republic Healthcare Ltd is 9.81 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Republic Healthcare Ltd (8357)?
The net margin of Republic Healthcare Ltd is −37.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Republic Healthcare Ltd (8357)?
The return on equity (ROE) of Republic Healthcare Ltd is −27.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Republic Healthcare Ltd (8357)?
On an EBIT basis the return on assets of Republic Healthcare Ltd is 1.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Republic Healthcare Ltd (8357)?
The operating margin of Republic Healthcare Ltd is −43.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Republic Healthcare Ltd (8357)?
Revenue at Republic Healthcare Ltd is growing −8.0% versus a year earlier (3y avg −6.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Republic Healthcare Ltd (8357) generate?
The free cash flow of Republic Healthcare Ltd is −HK$3.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Republic Healthcare Ltd (8357) hold?
Republic Healthcare Ltd holds more cash than debt, HK$1.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Republic Healthcare Ltd in the live analysis

One click puts Republic Healthcare Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.